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Abstract
Background: A major hurdle incurrent to the human clinical application of conditionally replicative adenovirus
(CRAd)-based virotherapy agents is their limited therapeutic efficacy. In this study we evaluated whether arming our
previously reported Ad5/3Δ24 CRAd vector containing a 24-base pair deletion in the E1A conserved region 2,
which allows selective replication within Rb-p16-deficient tumor cells, to express therapeutic genes could improve
oncolytic virus potency in ovarian cancer cells. We choose to assess the therapeutic benefits achieved by
virus-mediated expression of interleukin 24 (IL-24), a cytokine-like protein of the IL-10 family, and the inhibitor of
growth 4 (ING4) tumor suppressor protein.
Results: The generated CRAd-IL24 and CRAd-ING4 vectors were tested in ovarian cancer cell lines in vitro to
compare their replication, yield, and cytotoxic effects with control CRAd Ad5/3Δ24 lacking the therapeutic gene.
These studies showed that CRAd-IL24 infection resulted in significantly increased yield of infectious particles, which
translated to a marked enhancement of virus-induced cytotoxic effects as compared to CRAd-ING4 and non-armed
CRAd. Testing CRAd-IL24 and CRAd-ING4 vectors combined together did not revealed synergistic effects exceeding
oncolytic potency of single CRAD-IL24 vector. Both CRAds were also tested along with anti-VEGF monoclonal
antibody Avastin and showed no significant augmentation of viral cytolysis by anti-angiogenesis treatment in vitro.
Conclusions: Our studies validated that arming with these key immunomodulatory genes was not deleterious to
virus-mediated oncolysis. These findings thus, warrant further preclinical studies of CRAd-IL24 tumoricidal efficacy in
murine ovarian cancer models to establish its potential utility for the virotherapy of primary and advanced
neoplastic diseases.
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Background
In the past two decades, gene therapy has been developed as
a promising approach to combat a variety of diseases. Over
this time period, more than 2210 clinical gene therapy trials
were conducted, with 64 % addressing cancer [1]. Adenoviral
vectors have been used in 22 % of clinical trials, followed by
retroviral vectors (18.4 %) and naked/plasmid DNA (17.4 %).
Human adenovirus [2] (Ad) has been used extensively
to develop replication-deficient gene delivery vectors
and conditionally-replicative Ad (CRAd) agents for
cancer treatment. We have previously evaluated several
gene therapy strategies including oncolytic CRAd
virotherapy for ovarian cancer [3, 4]. This approach
takes advantage of the propensity of human Ad to infect
and replicate in epithelial cells, the origin of most
human cancers, while promoting cell lysis to facilitate
release of viral progeny [2]. These features have been
exploited by a number of strategies aimed at creating
oncolytic CRAd vectors with increased selectivity for
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cancer cells [5]. The biologic basis of the CRAd’s anti-
neoplastic effect is target cell selective replication
whereby direct oncolysis achieves specific tumor cell
killing. Progeny virions generated in this process may
thereby maintain the replicative cycle via lateral infec-
tion of adjoining tumor cells. This novel paradigm of
amplification has rationalized the rapid translation of
CRAd agents to the context of human clinical trials for
a variety of neoplastic disease targets.
Of note, we showed that the clinical utility of CRAds
derived from Ad serotype 5 (Ad5) for oncolytic treatment
of ovarian carcinoma is hampered by inefficient infection of
ovarian cancer (OvCa) cells. This is due to the paucity of
coxsackievirus group B and Ad receptor (CAR), the pri-
mary Ad5 receptor [6–8]. To confer CAR-independent
virus tropism we used genetic incorporation of RGD-4C
(Cys-Asp-Cys-Arg-Gly-Asp-Cys-Phe-Cys) targeting peptide
into Ad5 fiber knob domain [9]. Alternatively, we have
endeavored replacement of the knob for its counterpart
from Ad serotype 3 [10] that recognizes an alternative
receptor, desmoglein 2 [11], a receptor which appears to be
more abundantly expressed in ovarian cancer cells [12, 13].
These capsid modifications were employed to alter tropism
of CRAd Delta-24 [14], which contains a 24-base pair
deletion in the E1A conserved region 2 (CR-2) allowing
selective replication within Rb-p16-deficient tumor cells
[15]. Of note, this is a defect observed in most ovarian
cancer cells [16, 17]. We showed that Delta24-RGD and
Ad5/3Δ24 CRAd derivatives exhibit superior anti-tumor ef-
ficacy in murine models of carcinoma of the ovary [18–20].
On this basis, we have carried out Phase I human clinical
trials with both agents whereby their safety has been vali-
dated [21, 22]. In the aggregate, these human studies have
highlighted the overall safety of CRAd-based interventions.
However, a single modality approach may not be suffi-
cient to eradicate cancer in a patient, because most
cancers arise from abnormalities in multiple genetic and
signal transduction pathways. To overcome this CRAd
shortcoming new oncolytic agents were engineered to
contain therapeutic transgenes encoding an apoptosis-
inducing and immunomodulatory cytokines. Melanoma
differentiation associated gene 7 (MDA-7)/IL-24, a se-
creted protein of the IL-10 family, functions as a cytokine
at normal physiological levels expressed in tissues of the
immune system, has shown a great potential as an anti-
cancer gene [23]. At supra-physiological levels, MDA-7/
IL-24 plays a prominent role in inhibiting tumor growth,
invasion, metastasis and angiogenesis resulting in selective
cancer cell death without affecting normal cells [24]. The
expression of IL-24 mediated by replication-deficient Ad
vectors was shown to activate multiple proapoptotic path-
ways, culminating in decreased ovarian tumor cell survival
[25–27]. The inhibitor of growth (ING) family proteins
have been defined as candidate tumor suppressors [28]. A
novel member of ING family ING4 has potential sup-
pressive effect on different tumors via multiple path-
ways [29–33]. The use of replication-deficient Ad vectors
to express ING4 gene demonstrated improved therapeutic
efficacy and growth suppression of lung, pancreatic, and
breast carcinoma tumor xenografts [34–36]. Enhanced
tumor suppression was shown by nonreplicating bicistro-
nic Ad vector expressing both ING4 and IL-24 genes
employed for treatment of human non-small cell lung
cancer, breast cancer, and hepatocarcinoma subcutaneous
tumor xenografts [37–40]. These studies suggest that
arming CRAd vector with tumor suppressors such as
ING4 and IL-24 may constitute a novel and effective
therapeutic strategy for cancer virotherapy. It was previ-
ously shown that Ad5-based CRAd vector engineered to
contain the E1A gene under transcriptional control of the
promoter region of rodent progression elevated gene-3
and simultaneously express IL-24 gene in place of the
deleted E3 region, referred to as cancer terminator virus
(CTV), eradicates both primary and distant human breast
carcinoma, melanoma, and therapy-resistant prostate can-
cer cells xenotransplanted in athymic nude mice [41–45].
Our recent studies using novel fiber-chimeric Ad.5/3-
CTV CRAd demonstrated improved CAR-independent
infection efficiency in low CAR human prostate cancer
cells as compared to Ad.5-CTV in vitro while resulting in
potent suppression of tumor xenograft growth in a nude
mouse model [46, 47] and in a spontaneously induced
prostate cancer in Hi-myc transgenic mice [48].
Based on these encouraging data we constructed Ad5/
3Δ24 CRAd derivatives armed with IL-24 or ING4 gene
and tested their oncolytic potency in human ovarian
cancer cell lines and immortalized normal ovarian surface
epithelial cells. Herein we present evaluation of the gener-
ated CRAd-ING4 and CRAd-IL24 vectors either alone, or
together, as compared to control CRAd Ad5/3Δ24 lacking
the therapeutic gene. Armed and control CRAds were also
tested along with anti-VEGF monoclonal antibody Avastin
(Bevacizumab) to see whether their tumoricidal effects
could be affected by anti-angiogenesis treatment in vitro.
Overall, these studies revealed that oncolytic potency of
CRAd-IL24 is significantly increased as compared to
control CRAd and CRAd-ING4 thus, providing a strong
rationale for further preclinical testing of CRAd-IL24
therapeutic utility against carcinoma of the ovary.
Methods
Cells
The 911 human embryonic retinoblasts derived by trans-
formation with a plasmid containing 79–5789 bp of the
Ad5 genome [49] were obtained through Crucell Holland
B.V. (Leiden, The Netherlands). The human lung carcin-
oma cell line A549, ovarian adenocarcinoma cell line
OVCAR3 and OV-4 were obtained from American Cell
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Type Culture Collection (ATCC, Manassas, Virginia
USA). The human ovarian carcinoma cell line SKOV3.ip1
was obtained from Janet Price (M. D. Anderson Cancer
Center, Houston, Tex.). The normal ovarian surface epi-
thelial cells IOSE-120 (Passage 8) and IOSE-523 (Passage
8), which were obtained from healthy women and immor-
talized with SV40 T/t were received from Canadian
OvCaRe Cell Bank (Vancouver, B.C., Canada). The IOSE-
120 and IOSE-523 cells were maintain in a combination
of 199 (Sigma M5017) and MCDB105 (Sigma M6395)
medium (1:1) supplemented with 5 % FBS and 50 μg/ml
gentamicin. All cell lines were grown at 37 °C in medium
recommended by the suppliers in a humidified atmosphere
of 5 % CO2.
Construction of CRAd vectors
The construction of Ad5/3Δ24 CRAd, which contains
deletion of 24 nucleotides (bp 923 – 946) corresponding
to the amino acid sequence 122LTCHEAGF129 of the
E1A protein necessary for Rb protein binding [14] and
has the Ad serotype 3 knob domain incorporated into
the Ad5 fiber, was described previously [19, 22]. The
genome of CRAd-IL24 armed with human IL-24 was
generated as follows. First, the expression cassette con-
taining IL-24 gene under transcriptional control of hu-
man cytomegalovirus (CMV) immediate-early promoter/
enhancer and followed by synthetic polyadenylation sig-
nal, which was constructed as we described previously
[48] was cloned into pE3B shuttle plasmid [50] between
BamHI and SalI restriction sites. The constructed
pE3BzCMV-IL24 plasmid DNA was linearized and used
for homologous recombination with plasmid carrying
CRAd Ad5/3Δ24 genome [51] in E. coli BJ5183 cells as
described elsewhere [50]. The resultant plasmid carrying
the recombinant Ad5/3Δ24cmvIL24 genome containing
the CMV promoter-driven IL-24 gene in place of the
deleted E3B region was selected using zeocin, cut with
PacI to release CRAd-IL24 genome to transfect 911B
cells. To construct the genome of CRAd-ING4 armed
with homo sapiens ING4 we used shuttle plasmid
pE3BzCMV-ING4 containing CMV promoter driving
the expression of ING4 mRNA transcript isoform 9
(Accession No. NM_001127582), which was synthesized
by GenScript USA Inc. (ORF sequence 750 bp, Clone
ID: OHu26376C). The pE3BzCMV-ING4 plasmid DNA
was linearized and used for homologous recombination
with plasmid carrying CRAd Ad5/3Δ24 genome to
generate the recombinant Ad5/3Δ24cmvING4 genome
as described above. To construct the genome of non-
armed CRAd control we used plasmid pCMV-GLuc2
(New England BioLabs Inc., Ipswich, MA USA) that
encodes the secreted luciferase (Gluc) from the copepod
Gaussia princeps to excise the Gluc reporter gene and
clone it under CMV promoper in pE3B shuttle plasmid.
The constructed pE3BzCMV-Gluc plasmid was linearized
and used for homologous recombination with plasmid
carrying CRAd Ad5/3Δ24 genome to generate the recom-
binant Ad5/3Δ24cmvGluc genome as described above.
The generated Ad5/3Δ24cmvIL24, Ad5/3Δ24cmvING4,
and Ad5/3Δ24cmvGluc plasmids were digested with PacI
to release viral genomes to transfect 911B cells and
rescue CRAd-IL24, CRAd-ING4, and non-armed control
CRAd, respectively.
The newly rescued CRAd vectors were propagated on
A549 cells, purified by centrifugation on CsCl gradients
according to standard protocol, and dialyzed against
phosphate-buffered saline (PBS) (8 mM Na2HPO4,
2 mM KH2PO4 [pH 7.4], 137 mM NaCl, 2.7 mM KCl]
containing 10 % glycerol. The titers of physical viral
particles (vp) were determined by the methods of Maizel
et al. [52]. The titers of infectious viral particles were
determined by plaque assay using 293 cells as described
by Mittereder et al. [53]. The ratios of viral parti-
cles to plaque-forming units determined for CRAd-
IL24, CRAd-ING4, and CRAd control were 20, 30,
and 25 respectively.
Western blot and ELISA
Samples of SKOV3ip.1 cells infected with CRAd-ING4 at
the MOIs of 100, 33, and 11 vp/cell or uninfected control
cells were boiled in Laemmli loading buffer and were
loaded on a 4–20 % gradient SDS-PAGE gel (Pierce,
Rockford, IL). Electrophoretically resolved proteins were
transferred to a polyvinylidene fluoride membrane and
analyzed for the presence of ING4 polypeptides using
polyclonal rabbit antibody raised against ING4 internal re-
gion (Assay Biotechnology Company, Inc) diluted 1:1000
for overnight incubation at 4 °C. Bound rabbit antibodies
were detected with a secondary goat anti-rabbit or goat
anti-mouse antibody conjugated with alkaline phos-
phatase (Sigma, St. Louis, MO) and developed with
alkaline phosphatase substrate kit (Bio-Rad Laboratories,
Hercules, CA). The expression of IL-24 was confirmed
using OmniKine™ Human IL-24 ELISA kit as recom-
mended by the manufacturer (Assay Biotechnology
Company, Inc.) to detect and quantify IL-24 concentra-
tions in culture medium collected from cells infected
with CRAd-IL24 at the MOIs of 10 and 1 vp/cell or
uninfected control cells.
CRAd genome quantification
Monolayers of SKOV3ip.1, SKOV3luc, OV-4, and OVCAR3
OvCa cells plated in 6-well tissue culture plates at 5 × 105
cells/well were infected with each CRAd vector at the
MOI of 10 vp/cell. Total DNA was purified from the cells
harvested from each well 3 days postinfection using
QIAamp DNA Mini Kit (QIAGEN, Valencia, CA) as
recommended by the manufacturer. The levels of viral
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genome content were determined in triplicate DNA
samples extracted from each cell monolayer by real-time
PCR analysis using Light Cycler 480 System (Roche Diag-
nostics, Indianapolis, IN) with TaqMan primers and probe
designed for Ad hexon gene. Resultant viral genome copy
number was normalized by amount of cellular DNA,
which was determined in the same sample with primers
and probe specific for human β-actin (housekeeping gene)
using duplexing TaqMan PCR settings.
CRAd progeny amplification assay
Monolayers of SKOV3ip.1, SKOV3luc, OV-4, and OVCAR3
OvCa cells plated in 6-well tissue culture plates at 5 × 105
cells/well were infected with each CRAd vector at the MOI
of 10 vp/cell and incubated for 6 days to obtain complete
cytopathic effect (CPE). The monolayers of A549 cells were
infected with serial dilutions of lysates of the indicated
OvCa cells, which were infected with CRAd-ING4, CRAd-
IL24, or control CRAd to determine a cytotoxic endpoint
effect (50 % CPE or tissue culture infective dose TCID50)
6 days postinfection. The titers of infectious viral
progeny produced in each cell line were determined
using the Viral ToxGlo assay (Promega Corporation,
Madison, WI) to measure cellular ATP level as rec-
ommended by the manufacturer.
Analysis of oncolytic CRAd effects
Monolayers of OvCa cells or immortalized ovarian sur-
face epithelial cells grown in 96-well plates (3 × 103 to
5 × 103 cells/well) were infected in triplicates with
CRAd-ING4, CRAd-IL24, or control CRAd at the MOIs
ranging from 0.014 to 100 vp/cell. The decrease of cell
viability due to the virus-induced cell killing was mea-
sured 6 days post-infection using the Cell Proliferation
Assay (Promega Corporation, Madison, WI) as recom-
mended by the manufacturer. Assay was performed by
adding 10 μL CellTiter 96 AQueous One Solution Re-
agent directly to culture wells containing red phenol red
free media supplemented with 2 % FBS, incubating for
2 h and then recording the absorbance at 490 nm with a
plate reader (Synergy HT, Bio-Tek Instruments, Winooski,
VT). The data are presented as the percentages of viable
cells in monolayers infected with each viral dose that
were determined with respect to the uninfected control
set as 100 %.
To assess the CPE induced by virus propagation cells
grown in a 24-well plate (3 × 105 to 5 × 105 cells/well)
were infected in triplicates with each CRAd vector at the
MOIs ranging from 0.014 to 100 vp/cell. Plates were
incubated for 6 days at 37 °C and the cell monolayer
integrity was assessed by staining attached cells with
crystal violet and then scanning wells using Synergy HT
plate reader (Bio-Tek Instruments, Winooski, VT) set at
565 nm. The absorbance values detected in monolayers
infected with each viral dose were used to calculate the
percentage of cell density in infected cell monolayers
with respect to the uninfected control.
To monitor cytotoxic effects induced by each CRAd
alone or together the cell monolayers grown in 96-well
plates (3 × 103 to 5 × 103 cells/well) were infected with
each CRAd alone or two CRAd vectors together at MOI
of 1 vp/cell. The infected and uninfected cells were
subjected to CellTox™ Green Cytotoxicity assay as rec-
ommended by the manufacturer (Promega Corporation,
Madison, WI) by adding DNA-binding cyanine dye on
day 3 and monitoring the increase in fluorescent signal
intensity proportional to cytotoxicity till day 5 post-
infection to detect the level of CRAd-mediated cell killing
using the Synergy-HT plate reader (Bio-Tek Instruments,
Winooski, VT) with 485 nm excitation and 520 nm
emission wavelength filters.
Analysis of cytotoxic CRAd effects combined with Avastin
The monolayers SKOV3ip.1, OV-4, and OVCAR3 OvCa
cells were infected with each CRAd alone or two CRAd
vectors together at MOI of 10 vp/cell. Avastin obtained
through the Alvin J. Siteman Cancer Center pharmacy at
Barnes-Jewish Hospital (Washington University School
of Medicine, St. Louis) was used to supplement infection
and mock infection medium at the concentrations
ranging from 0 to 500 μg/ml. The infected and unin-
fected cells were subjected to CellTox™ assay (Promega
Corporation, Madison, WI) by adding DNA-binding
cyanine dye on day 3 and monitoring the increase in
fluorescent signal intensity till day 5 post-infection to de-
tect cell killing effects. The cells in 96-well plates were red
using the Synergy-HT plate reader (Bio-Tek Instruments,
Winooski, VT) with 485 nm excitation and 520 nm
emission filters.
The Cell Proliferation Assay (Promega Corporation,
Madison, WI) was carried out 6 days post-infection by
adding 10 μL CellTiter 96 AQueous One Solution Re-
agent directly to culture wells incubating for 1–2 h and
then recording the absorbance at 490 nm with a plate
reader (Synergy HT, Bio-Tek Instruments, Winooski,
VT) to detect cells that stayed alive after exposure to
CRAd and/or Avastin. The plates were red using the
Synergy-HT plate reader set at 490 nm. The mean values
of optical density (OD) detected for each Avastin con-
centration are presented after subtracting background
signal detected in monolayers that were not treated with
virus or Avastin.
Statistical analysis
All data are presented as the mean ± SD. The Student’s
two-tailed t-test was used to determine statistical signifi-
cance at the 95 % confidence level, with p ≤ 0.05 being
considered significantly different.
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Results
Construction and molecular validation of Ad vectors
In the current study we designed and constructed three
CRAds that are illustrated in Fig. 1. We used the back-
bone of previously described CRAd Ad5/3Δ24 [19] to
incorporate the CMV promoter-driven expression cas-
sette containing either IL-24 or ING4 therapeutic gene
within the early E3 region in place of the deleted E3B
genes to generate CRAd-IL24 or CRAd-IN4, respect-
ively. The control CRAd was constructed to express the
Gluc reporter gene encoding naturally secreted lucifer-
ase derived from the copepod, Gaussia princeps. The
generated CRAd-IL24 and CRAd-IN4 were tested along
with control CRAd vector to validate hypothesis that
arming Ad5/3Δ24 with IL-24 or ING4 therapeutic pay-
load may improve oncolytic CRAd potency following
infection ovarian cancer cells in vitro and in vivo. To
this end, the expression of IL-24 and ING4 genes was
validated in several ovarian cancer cell lines infected
with CRAd-IL24 or CRAd-IN4 vectors. Fig. 2a shows
that the presence of IL-24 was confirmed by ELISA at
concentrations ranging from 10 to 1000 ng/ml of culture
medium collected from ovarian cancer cells OV-4,
OVCAR3, SKOV3ip.1, and normal IOSE523 cells, which
were infected with CRAd-IL24, but not in mock-
uninfected cells (data not shown). Western blot analysis
of ING4 expression in SKOV3ip.1 cells infected with
CRAd-ING4 at varying MOIs demonstrated a vector
dose-dependent increase of 29 kDa protein band inten-
sity, which corresponds to ING4 polypeptide molecular
mass as compared to uninfected cells (Fig. 2b). To deter-
mine whether arming with IL-24 or ING4 therapeutic
genes leads to improved oncolytic CRAd potency we
tested cell viability and cytotoxicity following infection
of normal and ovarian cancer (OvCa) cells.
Evaluation of CRAd replication efficacy in vitro
To analyze CRAd replication we determined the levels
of genome and viral progeny amplification following
infection OvCa cells. As illustrated in Fig. 3, CRAd-
ING4 vector demonstrated the highest levels of genomic
DNA amplification, which was detected in SKOV3ip.1,
SKOV3luc and OVCAR3 cells 3 days postinfection using
TaqMan qPCR while CRAd-IL24 vector did not show
significant differences as compared to control CRAd. To
assess the infectious viral progeny produced by CRAd-
ING4, CRAd-IL24, or control CRAd following OvCa
cells infection the serial dilutions of their lysates were
used to inoculate monolayers of A549 cells to determine
a cytotoxic endpoint effect (50 % CPE or tissue culture
infective dose TCID50) 6 days postinfection. To this end,
we employed Viral ToxGlo assay (Promega) to measure
luminescent signal intensity dependent on cellular ATP
levels, as surrogate of infected cell viability, to detect the
decrease in A549 cell viability associated with increased
number of infectious CRAd progeny present in serial
dilutions of infected OvCa cell lysates. As can be seen in
Fig. 4, somewhat similar CRAd-IL24 and control CRAd
progeny titers were detected in OVCAR3 and OV-4 cells
while CRAd-IL24 infection of SKOV3ip.1 and SKOV3luc
cells resulted in significantly increased titers of infectious
progeny as compared to control CRAd. Despite the high-
est viral genomic DNA amplification demonstrated by
CRAd-ING4, it showed the lowest infectious progeny
titers in all OvCa cells tested. The lack of correlation
between viral genome amplification and infectious pro-
geny titers observed following CRAd-ING4 infection
suggested that ING4 expression may interfere with infec-
tious viral particles assembly within nucleus of infected
cells. In contrast to CRAd-ING4, it seems that amplifica-
tion of CRAd-IL24 infectious particles was not affected by
Fig. 1 Graphical representation of Ad vectors used in the study. The generated CRAd vectors have a deletion of 24 nucleotides (Δ24) in the early
E1A gene (E1A) to allow selective replication in tumor cells with an pRb mutation. All three vectors encode a chimeric fiber protein (5/3 fiber)
containing tail and shaft regions of Ad5 fiber fused with knob domain of Ad3, which is known to improve infection efficiency of OvCa cells.
CRAd-IL24 (Ad5/3Δ24cmvIL24) contains IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the hu-
man CMV promoter (CMVp). CRAd-ING4 (Ad5/3Δ24cmvING4) is armed with CMVp-driven Inhibitor of Growth 4 (ING4) gene. Non-armed CRAd
control was constructed to express reporter gene encoding the secreted Gaussia Luciferase (Gluc)
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IL24 gene expression while resulting in infectious
progeny titers similar or markedly increased as compared
to control CRAd.
Evaluation of oncolytic effects of CRAd vectors in vitro
To detect the effects of IL-24 or ING4 gene expression
on CRAd potency we infected monolayers of normal
ovarian surface epithelial cells IOSE-120 and IOSE-523
or OvCa cells at MOIs ranging from 0.4 to 100 vp/cell
and tested cell viability 6 days postinfection. As can be
seen in Fig. 5a, we did not observed any significant
differences in proliferation of cells infected with armed
CRAds as compared to control CRAd. Both IOSE-523
and OVCAR3 cells were very susceptible to CRAd infec-
tion resulting in 50 % live cells at the MOI of 1 and 0.4,
respectively as compared to uninfected cells. IOSE-120
and OV-4 were relatively resistant to CRAd infection
while showing 50 % cell viability at MOI of 33. Infection
of SKOV3ip.1 and SKOV3luc cells revealed significant
differences in oncolytic CRAd potency. Both armed
CRAds significantly decreased cell viability at MOIs 0.4
and 1 as compared to control CRAd in SKOV3luc cells.
Infection of SKOV3ip.1 cells revealed that cytotoxic
CRAd-ING4 effects were markedly improved as compared
to control CRAd. On the other hand, while CRAd-IL24
vector demonstrated oncolytic potency significantly super-
ior to CRAd-ING4 vector. To see if combining armed
CRAds together may result in improved cytotoxicity we
tested viability of cells infected with both CRAd-IL24 and
CRAd-ING4 vectors as compared to control CRAd along
with either CRAd-IL24 or CRAd-ING4. As illustrated in
Fig. 5b (right panel), the cytotoxic effects induced in SKO-
V3ip.1 cells by of CRAd-IL24 and CRAd-ING4 together
were somewhat superior to CRAd-IL24 combined with
control CRAd and markedly improved with respect to
CRAd-ING4 combined with control CRAd. However, the
effects observed while using CRAd-IL24 and CRAd-ING4
vector together were not substantially different from those
seen with CRAd-IL24 alone at the same MOI (Fig. 5b, left
panel). We also could not detect substantial differences
between any CRAd combinations used to infect SKOV3-
luc cells (Fig. 5b, right panel). Despite somewhat dramatic
cytotoxicity increase was observed in SKOV3ip.1 cells
when CRAd-ING4 was combined with CRAd-IL24 vector
as compared to control CRAd these data suggested that
Fig. 2 Validation of CRAd-mediated expression of IL-24 and ING4 genes. a) The concentrations of IL-24 protein following infection of the
indicated OvCa cell lines and normal IOSE523 cells with CRAd-IL24 at the MOIs of 1 and 10 vp/cell were determined in cell culture supernatants
3 days postinfection using commercial ELISA kit with IL-24 concentration standards. Each bar represents the cumulative mean ± SD (*p≤ 0.05).
b) The relative levels of ING4 gene expression were determined following infection of SKOV3ip.1 cells with CRAd-ING4 at the MOIs of 100, 33,
and 11 vp/cell. The ING4 protein band of 29 kDa was detected in cell lysates 3 days postinfection with 100, 33, and 11 vp/cell, but not in
mock-infected cells (0 vp/cell) using Western blot with rabbit polyclonal Ab raised against ING4 internal region
Fig. 3 Amplification of CRAd genomes in OvCa cells. The relative
amplification of CRAd genome following OvCa cell infection was
determined 3 days postinfection using TaqMan qPCR primer/probe
to detect viral genome copy number in samples of total DNA
isolated from the indicated OvCa cell lines infected with CRAd-IL24,
CRAd-ING4, or control CRAd at the MOI of 10 vp/cell. Each bar
represents the cumulative mean Ad genome copy number/ng
β-actin DNA ± SD (*p ≤ 0.05)
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employing both armed CRAds together may benefit pri-
marily CRAd-ING4 vector rather than CRAd-IL24 vector.
Oncolytic CRAd effects were further assessed in OvCa
cells after staining adherent cells with crystal violet
6 days postinfection and determining the densities of cell
monolayers infected at various MOIs. The values of cell
density presented in Fig. 6a show markedly enhanced
cytopathic effects of CRAd-IL24 vector as compared to
both CRAd-ING4 and CRAd control in SKOV3ip.1 and
SKOV3luc cells. While cytopathic effects of CRAd-ING4
vector were significantly increased in SKOV3ip.1 cells
we did not detect a marked improvement of cytotoxicity
in SKOV3luc cells as compared to control CRAd vector.
While combining CRAd-IL24 and CRAd-ING4 vectors
produced cytopathic effects somewhat similar to CRAd-
IL24 alone in SKOV3ip.1 cells it resulted in a marked
loss of cytotoxicity in SKOV3luc cells as compared to
CRAd-IL24 alone (Fig. 6a). We observed that cytopathic
effects of CRAd-IL24 vector were somewhat increased at
lower MOIs in OVCAR3 cells as compared to CRAd-
ING4 and control CRAd vector however, no beneficial
effects of CRAd arming with IL-24 and ING4 genes were
revealed in OV4 cells (Fig. 6b).
To monitor CRAd-mediated cell killing effects we
employed CellTox™ Green Cytotoxicity assay (Promega).
The monolayers OvCa cells and normal IOSE-120 cells
were infected with each CRAd alone or two CRAd
vectors together at MOI of 1 vp/cell. The changes in
citotoxicity were detected by adding DNA-binding cya-
nine dye and measuring the levels of fluorescent signal
intensity in infected and uninfected cells, which is
proportional to number of killed cells on day 3, 4 and 5
postinfection (Fig. 7). We observed that infection of
SKOV3ip.1 cells with armed CRAds resulted in mark-
edly improved cell killing as compared to control CRAd
while no significant differences were detected between
armed and control CRAd vectors in IOSE-120, OV-4,
and OVCAR3 cells. As can be seen in Fig. 7a, the use of
CRAd-IL24 alone or in combination with either CRAd-
ING4 or control CRAd resulted in up to 4-fold increased
levels of cytotoxicity as compared to control CRAd
alone or together with CRAd-ING4, respectively. The
use of CRAd-ING4 alone showed only a marginal im-
provement in cell killing as compared to control CRAd.
Analysis of CRAd oncolysis in the presence of Avastin
To test tumoricidal effects of CRAd virotherapy combined
with anti-VEGF monoclonal antibody (mAb) Avastin
(Bevacizumab) we infected SKOV3ip.1, OV-4, and OVCAR3
cells with each CRAd alone or two CRAd vectors together
Fig. 4 CRAd progeny amplification in OvCa cells. The titers of infectious viral progeny produced in OvCa cell lines were determined using the
Viral ToxGlo assay (Promega) to measure cellular ATP level, as surrogate of cell viability. Monolayers of A549 cells were infected with serial
dilutions of lysates of the indicated OvCa cells, which were infected with CRAd-ING4, CRAd-IL24, or control CRAd to determine a cytotoxic
endpoint effect (50 % CPE or tissue culture infective dose TCID50) 6 days postinfection. Each data point represents the cumulative mean ± SD
(error bars are smaller than the symbols, p≤ 0.05)
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at the MOI of 10 vp/cell at day 0 while supplement-
ing culture medium with Avastin at the concentra-
tions ranging from 0 to 500 μg/ml. (Avastin™; Roche,
Switzerland, or Bevacizumab; Genentech BioOncology,
South San Francisco, CA, USA). The infected and
uninfected cells were subjected to CellTox™ assay
(Promega) by adding DNA-binding dye and measur-
ing the fluorescent signal intensity, which is propor-
tional to cytotoxicity on day 3, 4, and 5 post-infection
to assess the cell killing effects. Figure 8a (left panel)
shows that CRAd-IL24 alone and in combination with
either CRAd-ING4 or control CRAd demonstrated mark-
edly increased cell killing efficiency on day 3 postinfection
as compared to control CRAd alone. While CRAd-ING4
showed significantly increased cytotoxicity as compared to
control CRAd in SKOV3ip.1 cells, it was somewhat
decreased in OV-4 and OVCAR3 cells on day 3. When
cytotoxic effects were monitored on day 5 postinfection
Fig. 5 Analysis of cytotoxic CRAd effects in normal and OvCa cells. a) The monolayers of normal ovarian surface epithelial IOSE-120 and IOSE-523
cells or OV-4 and OVCAR3 OvCa cells were infected with each CRAd vector at the indicated MOIs (vp/cell). b) The monolayers SKOV3ip.1 and
SKOV3luc OvCa cells were infected with each CRAd alone (left panel) or two CRAd vectors together (right panel) at the indicated MOIs (vp/cell).
The infected and uninfected cells were stained using MTS-based Cell Proliferation Assay (Promega) 6 days postinfection to detect cells that
survived CRAd CPE. Live cells percentages are calculated with respect to mock-infected cell monolayers.. Each data point represents the
cumulative mean ± SD (some error bars are smaller than the symbols, p≤ 0.05)
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(Fig. 8a, left panel), we did not observe any consistent
differences between tested CRAds in OVCAR3 cells
while all CRAd combinations showed substantially
improved killing of SKOV3ip.1 cells and somewhat
increased cytotoxicity (except for CRAd-ING4) in OV-
4 cells as compared to control CRAd. Despite the
differences that we observed in CRAd-mediated cell
killing efficacy, it was not dependent on Avastin
Fig. 6 Evaluation of oncolytic effects of CRAd-IL24 or CRAd-ING4 alone and combined together. Monolayers of SKOV3ip.1, SKOV3luc, OVCAR3,
and OV-4 cells were infected with each CRAd alone (left panel) or two CRAd vectors together (right panel) at the indicated MOIs. Oncolytic effects
of CRAd vectors were assessed by determining cell monolayer integrity 6 days postinfection. The integrity of cell monolayers was determined by
staining adherent cells with crystal violet. The stained monolayers were scanned using a plate reader set at 565 nm to calculate the percentage
cell density in monolayers infected with each viral dose that were determined with respect to the uninfected control. Each data point represents
the cumulative mean ± SD (error bars are smaller than the symbols, p≤ 0.05)
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concentration suggesting that oncolytic CRAd effects
may not benefit from anti-angiogenesis treatment in
vitro. These data were corroborated by Cell Prolifera-
tion Assay (Promega) carried out 6 days postinfection
and showing no dose-dependent effects on a viability
of both infected and uninfected cells (Fig. 8b, right
column). Overall, these in vitro studies did not reveal
any evidence that anti-angiogenesis mAb treatment
has direct effect on OvCa cell viability in a wide range
of Avastin concentrations tested.
Discussion
The frequent resistance of aggressive cancers to currently
available therapies, such as radiotherapy and chemotherapy,
Fig. 7 Monitoring cytotoxic effects induced by CRAd-IL24 or CRAd-ING4 alone and together. The monolayers of SKOV3ip.1, OvCa OV-4, or
OVCAR3 ovarian cancer cells and normal ovarian surface epithelial IOSE-120 cells were infected with each CRAd alone (left panel) or two CRAd
vectors together (right panel) at MOI of 1 vp/cell. The infected and uninfected cells were subjected to CellTox™ Green Cytotoxicity assay
(Promega) by adding DNA-binding cyanine dye on day 3 and monitoring the increase in fluorescent signal intensity proportional to cytotoxicity
till day 5 postinfection to detect the level of CRAd-mediated cell killing using the Synergy-HT plate reader with 485 nm excitation and 520 nm
emission wavelength filters. Each data point represents the cumulative mean ± SD (some error bars are smaller than the symbols, p≤ 0.05)
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mandates development of targeted, nontoxic and more
efficacious treatment modalities. CRAd agents that
induce oncolysis by cancer-specific replication are
currently being evaluated in clinical trials [54, 55]
demonstrating high safety profile but limited clinical
efficacy. Further in this regard, arming CRAds with
immunomodulatory or proapoptotic genes is being
explored as a strategy to enhance their potency.
In this study we generated the derivatives of Ad5/
3Δ24 CRAd vector designed to express therapeutic
genes that could potentially improve viral oncolysis in
ovarian cancer cells. Based on previous encouraging data
using IL-24 gene to arm both Ad5-based and Ad5/3-
based CTV CRAd [41–48] we choose to test whether
our Ad5/3Δ24 vector designed to express IL-24 could
provide therapeutic benefit for oncolytic treatment of
carcinoma of the ovary. We also thought to assess the
utility of CRAd arming with ING4 gene, which was
previously shown to provide growth suppression of sev-
eral tumor types, when being expressed alone [34–36] or
together with IL-24 gene [37–40] using replication-
incompetent Ad vectors. To this end, we constructed
Ad5/3Δ24 CRAd derivatives containing either IL-24 or
ING4 gene controlled by constitutive CMV promoter
incorporated in place of the early E3B genes deleted
within viral chromosome (Fig. 1). Following validation of
Fig. 8 Analysis of cytotoxic CRAd effects combined with Avastin. a) The monolayers SKOV3ip.1, OV-4, and OVCAR3 OvCa cells were infected with
each CRAd alone or two CRAd vectors together at MOI of 10 vp/cell. Avastin was used to supplement infection and mock infection medium at
the indicated concentrations (μg/ml). The infected and uninfected cells were subjected to CellTox™ assay (Promega) by adding DNA-binding
cyanine dye on day 3 and monitoring the increase in fluorescent signal intensity, which is proportional to cytotoxicity till day 5 post-infection to
detect any cell killing effects. The cells in 96-well plates were red using the Synergy-HT plate reader with 485 nm excitation and 520 nm emission
filters. The data represent the mean values of relative fluorescent units (RFU) detected for each Avastin concentration after subtracting
background signal detected with cyanine dye added but no virus or Avastin. b) The Cell Proliferation Assay (Promega) was carried out 6 days
post-infection to detect cells that stayed alive after exposure to CRAd and/or Avastin. The plates were red using the Synergy-HT plate reader set
at 490 nm. The mean values of optical density (OD) detected for each Avastin concentration are presented after subtracting background signal
detected in monolayers that were not treated with virus or Avastin. Each data point represents the cumulative mean ± SD (error bars are smaller
than the symbols, p ≤ 0.05)
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efficient expression of IL-24 and ING4 genes in
OvCa cell lines infected with newly generated CRAds
(Fig. 2a, b) we carried out multiple assays to assess
the efficiency of virus replication and the extent of
induced cytotoxicity.
First, we determined the viral chromosome amplifica-
tion in OvCa cells infected with CRAd-ING4, CRAd-
IL24, control CRAd vector, which revealed that the
CRAd-ING4 genome copy numbers were significantly
increased as compared to CRAd-IL24 and control CRAd
in three out of four OvCa cell types tested (Fig. 3).
When the yield of infectious viral progeny produced in
these cells was determined based on TCID50 assay it
appeared that CRAd-ING4 infection resulted in signifi-
cantly lower titers of infectious virus as compared to
control CRAd in all tested OvCa lines. On the other
hand, CRAd-IL24 infectious progeny produced in SKO-
V3ip.1 and SKOV3luc cells was markedly increased with
respect to control CRAd (Fig. 4). This discrepancy
between viral genome amplification and the resultant
amount of infectious viral progeny indicated that overex-
pression of IL-24 and ING4 genes in infected cells may
affect the CRAd genome replication and/or subsequent
DNA packaging into fully assembled infectious virions.
While previous studies of CTV CRAd derivatives
[41–48] expressing IL-24 gene did not report any
drawbacks affecting viral progeny amplification and as-
sembly, therapeutic ING4 effects were analyzed in the
context of replication-incompetent Ad-based expression
[34–36]. It is likely that exogenous ING4 can control
cellular pathways interfering with CRAd Δ24 life cycle
following cancer cell infection. p29ING4 was reported to
interact with p300, a major component of histone acetyl
transferase complexes, and negatively regulate the cell
growth by decreasing cell population in S-phase, inducing
significant G2/M arrest of cell cycle and apoptosis
[56, 57]. In contrast to ING4, the E1A proteins facili-
tate cell cycle progression by binding to the p300 and
CBP proteins, which is mediated by CR-1 [58]. E1A
mutants lacking CR-2 and unable to bind pRB family
members can nevertheless stimulate cellular DNA synthe-
sis to move the infected cells from G1 to S phase allowing
efficient viral DNA replication [59, 60]. Therefore, the
published data and our own observations strongly suggest
that vector-mediated ING4 expression can suppress
cancer cell proliferative status thereby, creating an
environment unfavorable for CRAd propagation.
To evaluate oncolytic potency of armed CRAd-IL24
and CRAd-ING4 with respect to control CRAd we
carried out multiple assays measuring cell viability fol-
lowing infection at a wide range of MOIs. Analysis of
cell proliferation and cytotoxicity showed that oncolytic
potency of CRAd-IL24 was dramatically improved as
compared to non-armed CRAd and superior to CRAd-
ING4 in in SKOV3ip.1 cells. While CRAd-IL24 and
CRAd-ING4 infection resulted in somewhat similar cyto-
toxicity increase in SKO3luc cells as compared to control
CRAd we did not observe any significant differences
between CRAd vectors in OV-4 and IOSE-120/523 cells.
We also tested whether combining CRAd-IL24 and
CRAd-ING4 vectors may result in augmentated cytotox-
icity in OvCa cells as compared to their separate applica-
tion. When SKOV3ip.1 cells were infected with CRAd-IL24
mixed with equal amount of either CRAd-ING4 or un-
armed CRAd we observed an overall augmentation of
cytotoxic effects induced by CRAd-IL24/ING4 mix as
compared to CRAd-IL24/CRAd or CRAd-ING4/CRAd
mixture. However, the resultant oncolytic effects detected
in all tested OvCa cells were not increased above the level
induced by the same viral particle number of CRAd-IL24
along. Hence, these experiments did not reveal any signifi-
cant benefits while combining CRAd/IL-24 and CRAd-
ING4 together, thereby, indicating that the predominant
pathways that mediate IL-24 and ING4 therapeutic effects
are not synergistic in vitro.
Finally, we tested if supplementing infection media with
Avastin (Bevacizumab), a recombinant humanised mo-
noclonal antibody developed against soluble VEGF to
prevent receptor binding [61], may increase oncolytic
potency of CRAd-IL24 and/or CRAd-ING4 in OvCa cells.
Interestingly, some recent studies indicate that in addition
to inhibition of angiogenesis high doses of Avastin may
have direct anti-cancer cell properties in vitro [62]. To
address this issue we monitored cytotoxic effects induced
by each CRAd alone or two CRAds added together in
the presence of increasing concentrations of Avastin
(0–300 μg/ml). The cytotoxic effects measured on day 3
and 5 post-infection demonstrated that the CRAd-
mediated cell-killing in SKOV3ip.1, OV-4, and OVCAR3
cultures was essentially the same in the absence or pres-
ence of Avastin at a wide range of concentrations tested
(Fig. 8a). These data were supported by cell viability assay
carried on day 6 post-infection, which did not show any
significant reduction of cell viability caused by CRAd
vectors in the presence of Avastin (Fig. 8b). The treat-
ments of cell monolayers with indicated Avastin concen-
trations did not reveal significant cytotoxic or proliferative
effects except for OV-4 cells at day 5 postinfection, which
was not concentration-dependent and could be caused
by other factors. Collectively, these data along with
previous studies [63] indicate the lack of direct anti-
cancer properties in vitro. On the other hand, this
assay (Fig. 8a) corroborated our previous observations
that CRAd-IL24 oncolytic function is markedly super-
ior to both CRAd-ING4 and control CRAd, thus,
validating that observed increase of infectious CRAd-
IL24 vector yields (Fig. 4) can translate to enhanced
cell-killing efficacy (Figs. 5b, 6, 7a, 8a).
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Conclusions
In the aggregate, our in vitro findings warrant further
preclinical studies of CRAd-IL24 to test its efficacy in
murine ovarian cancer models to establish its potential
utility for the virotherapy treatment of primary and
advanced neoplastic diseases.
Whereas oncolytic virotherapy agents were originally
designed to accomplish anti-neoplastic effects directly via
replicative oncolysis, it has recently become apparent that
they can also elicit potent immunogenic tumor cell death.
Specifically, virus infection of cancer cells releases damage-
associated patterns recognized by receptors expressed on
cells of the innate immune system. Activation of these
receptors induces pro-inflammatory cytokines provoking
Th1-type immune responses [64–66]. The recognition of
these potent immunostimulatory effects of virotherapy
agents has led to the design of strategies to augment active
anti-tumor immunization using armed CRAd agents
[67–69]. This recognition now allows us to determine
the full utilities that derive from our CRAd-IL24
agent in preclinical studies employing immunocompe-
tent syngenic murine ovarian cancer model [70].
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